Acurx reports 96% clinical cure rate in Phase 2 trial of ibezapolstat for C. difficile infection

Acurx Pharmaceuticals, Inc.

96% clinical cure rate (25/26 patients) in combined Phase 2a and 2b trials of ibezapolstat.
Ibezapolstat well tolerated; no drug-related serious adverse events; three mild GI events resolved.
Phase 2b vancomycin-controlled segment terminated early based on high observed cure rate.
Company plans End-of-Phase 2 FDA meeting in Q1 2024 and advancement to Phase 3.
Additional analyses of sustained cure, microbiome, and bile acids are forthcoming.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.